Pasithea Therapeutics (KTTA) Competitors

Pasithea Therapeutics (NASDAQ:KTTA) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.

Do institutionals & insiders have more ownership in KTTA or SLGL?

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor KTTA or SLGL?

Sol-Gel Technologies received 147 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 63.40% of users gave Sol-Gel Technologies an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote.

Company	Underperform	Outperform
Pasithea Therapeutics	Outperform Votes 2 40.00%	Underperform Votes 3 60.00%
Sol-Gel Technologies	Outperform Votes 149 63.40%	Underperform Votes 86 36.60%

Which has higher earnings and valuation, KTTA or SLGL?

Pasithea Therapeutics has higher earnings, but lower revenue than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$15.96M	-$12.69	-0.13
Sol-Gel Technologies	$11.71M	1.81	-$27.24M	-$0.34	-2.24

Which has more volatility and risk, KTTA or SLGL?

Pasithea Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Is KTTA or SLGL more profitable?

Pasithea Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -81.75%. Sol-Gel Technologies' return on equity of -27.17% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-81.57%	-74.31%
Sol-Gel Technologies	-81.75%	-27.17%	-22.49%

Does the media refer more to KTTA or SLGL?

In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 3 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.57 beat Sol-Gel Technologies' score of 0.44 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend KTTA or SLGL?

Sol-Gel Technologies has a consensus target price of $5.00, suggesting a potential upside of 557.89%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sol-Gel Technologies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Sol-Gel Technologies beats Pasithea Therapeutics on 12 of the 16 factors compared between the two stocks.